Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans

Erythema Chronicum Migrans Clinical Trial

Official title:

Comparison of Doxycycline and Cefuroxime Axetil in Patients With Erythema Migrans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03584919
• Other study ID #: Doxy-Zinnat
• Status: Completed
• Phase: N/A
• Start date: June 1, 2006
• Est. completion date: September 30, 2007

Study information

• Verified date: June 2018
• Source: University Medical Centre Ljubljana
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A European, prospective clinical trial in which doxycycline and cefuroxime axetil were compared in the treatment of adult patients with erythema migrans included a control group to address this question. Evaluations of patients were conducted at baseline, 14 days and 2, 6, and 12 months after enrollment. Control subjects were evaluated at baseline and at 6 and 12 months. Subjective complaints that newly developed or intensified since the onset of erythema migrans or since the date of enrollment for controls were referred to as "new or increased symptoms"(NOIS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 509
• Est. completion date: September 30, 2007
• Est. primary completion date: September 30, 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• typical solitary erythema migrans as defined by the United States Centers for Disease Control and Prevention. In addition, patients with skin lesion <5 cm in diameter were also included if they recalled a recent tick bite at the site of the skin lesion, had a symptom-free interval between the bite and the onset of the lesion, and reported an expanding skin lesion prior to diagnosis.

Exclusion Criteria:

• Lyme disease previously

• pregnancy or lactation

• immunocompromised

• serious adverse reaction to a beta-lactam or tetracycline drug in the past

• received an antibiotic with known anti-borrelial activity within 10 days

• multiple erythema migrans lesions

• presence of an extracutaneous manifestation of Lyme disease

Related Conditions & MeSH terms

• Erythema
• Erythema Chronicum Migrans

Intervention

Drug:
• doxycycline
patients received oral doxycycline 100 milgrams bid for 15 days
• Cefuroxime Axetil 500Mg Tab
patients received cefuroxime axetil 500 milgrams bid for 15 days

Other:
• control subjects
no intervention

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Centre Ljubljana

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Objective Manifestations and Subjective New or Increased Symptoms (NOIS) in Patients Treated for Erythema Migrans With Doxycycline or Cefuroxime Axetil for 15 Days	At each visit patients were examined and asked about the presence of any symptoms that newly developed or had worsened since erythema migrans. If such symptoms had no other medical explanation they were regarded as new or increased symptoms (NOIS). Complete response was defined as absence of any manifestations of Lyme borreliosis, with return to pre-Lyme borreliosis health status. Partial response was defined as presence of NOIS. Failure was defined as presence of objective manifestations of Lyme borreliosis or persistence of Borrelia burgdorferi sensu lato in skin at the site of the previous erythema migrans.	One year follow-up (follow-up time points at 14 days, 2 months, 6 months, and 12 months after enrolment)
Secondary	Number of Patients (at 12 Months After Treatment With Doxycycline or Cefuroxime Axetil for 15 Days for Erythema Migrans) and Number of Control Subjects (Without a History of Lyme Borreliosis) With Nonspecific Symptoms.	12 months after treatment patients and controls were asked to complete a written questionnaire asking whether they had had any of 8 nonspecific symptoms (fatigue, arthralgias, headache, myalgias, paresthesias, concentration difficulties, or irritability) within the preceding week. For both patients and controls, the severity of each individual symptom was graded by the subject on a 10-cm visual analog scale (10 = most severe).	12 months after treatment